Genta Incorporated (Genta) is a biopharmaceutical company that specializes in the discovery, development and commercialization of drugs for the treatment of cancer and related diseases. The company's research focuses mainly on DNA/RNA Medicines and Small Molecules. Genta markets Ganite, in the US, a drug indicated for the treatment of cancer-related hypercalcemia. The company has developed proprietary oral formulations of the active ingredient in Ganite, which are being evaluated as potential treatments for diseases associated with accelerated bone loss. The company's headquarters is in Berkeley Heights, New Jersey, US. In August 2012 the company filed for bankruptcy. In July 2016, Genta Incorporated went out of business as per its Chapter 7 liquidation filing under bankruptcy.